1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). NIAID invites small business grant applications proposing to test and evaluate non-viral technologies capable of delivering RNA-based therapeutics into disease-relevant cells and tissues in vivo.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-NS-24-068: Notice of NINDS Participation and Interests in NOT-AI-24-007 "Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH)" Notice of NINDS Participation and Interests in NOT-AI-24-007 "Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH)" February 2, 2024 - Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH).
See Notice NOT-AI-24-007 . National Institute of Neurological Disorders and This Notice announces the participation of the National Institute of Neurological Disorders and Stroke (NINDS) in NOT-AI-24-007 "Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH)," effective May 12, 2024.
Changes to the NOSI are shown below: National Institute of Allergy and Infectious Diseases ( NIAID ) National Center for Advancing Translational Sciences ( NCATS ) National Cancer Institute ( NCI ) Research Topics of Interest Delivery of RNA therapeutics and/or genome editors for the treatment of rare diseases; broad spectrum delivery technologies for RNA therapeutics and/or genome editors that go to multiple tissues; technologies to target RNA therapeutics and/or genome editors to specific cells and tissues; delivery technologies based on phages.
National Institute of Allergy and Infectious Diseases ( NIAID ) National Center for Advancing Translational Sciences ( NCATS ) National Cancer Institute ( NCI ) National Institute of Neurological Disorders and Stroke (NINDS) Research Topics of Interest Delivery of RNA therapeutics and/or genome editors for the treatment of rare diseases; broad spectrum delivery technologies for RNA therapeutics and/or genome editors that go to multiple tissues; technologies to target RNA therapeutics and/or genome editors to specific cells and tissues; delivery technologies based on phages.
National Institute of Neurological Disorders and Stroke (NINDS) The National Institute for Neurological Disorders and Stroke (NINDS) is interested in applications to NOT-AI-24-007 that fall within the NINDS mission space.
Particular areas of interest include: Delivery methods and strategies that enable transport of RNA-based therapeutics across the blood-brain barrier Delivery methods and strategies that target RNA-based therapeutics to specific regions of the peripheral and/or central nervous system Delivery methods and strategies that target RNA-based therapeutics to specific cell populations of the peripheral and/or central nervous system Strategies for sustained expression and/or activity of RNA-based therapeutics targeted to cells of the peripheral and/or central nervous system NINDS may decline funding of any application for programmatic or administrative reasons.
Potential applicants are strongly encouraged to contact program staff early in the process of preparing a submission. To learn more about the NINDS Small Business Program please visit https://www. ninds.
nih. gov/funding/ninds-small-business-program . Part 2.
Section VII. Agency Contacts Scientific/Research Contact(s) National Institute of Neurological Disorders and Stroke (NINDS) Financial/Grants Management Contact(s) Chief Grants Management Officer National Institute of Neurological Disorders and Stroke (NINDS) All other aspects of this Notice remain the same.
Please direct all inquiries to: National Institute of Neurological Disorders and Stroke (NINDS) Weekly TOC for this Announcement NIH... Turning Discovery Into Health ®
According to the current listing, eligibility includes: Small businesses proposing to test and evaluate non-viral technologies for RNA-based therapeutic delivery. Must submit through an NIH SBIR or STTR Notice of Funding Opportunity (NOFO). Confirm the full requirements in the official notice before applying.
Applications for RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) are due January 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) is funded by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
National Institute of Allergy and Infectious Diseases (NIAID) Resource-Related Research Projects (R24 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This grant supports resource development projects to advance infectious disease and immunology research. It focuses on developing and enhancing resources that facilitate research in these critical areas.
National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This funding opportunity supports investigator-initiated clinical trials requiring enhanced oversight, with durations up to 7 years. While focused on clinical trials, modeling can be a critical component of trial design and analysis in infectious diseases and immunology.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read article